Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
El Instituto de Oncología de Vall d’Hebron (VHIO) junto con el Hospital Universitario Vall d’Hebron (HUVH) han unido fuerzas para…
Barcelona, 16 October 2014. The Vall d´Hebron Institute of Oncology (VHIO) and the Vall d´Hebron University Hospital (HUVH) have joined…
➢ The combination of chemotherapy and selective therapy with trastuzumab has for the very first time been shown as an…
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates ‘unprecedented’ benefit Lugano/Madrid, 28 September 2014 — Patients with HER2-positive…
Barcelona, 26 September 2014 – Officially announced today during a press conference at the 2014 Congress of the European Society…
Barcelona, 18 September 2014 – Officially celebrated during yesterday´s award ceremony of the Spanish Association Against Cancer (AECC), presided by…
Latest research at VHIO confirms 4 subgroups of HER2+ breast cancer with different molecular characteristics The diagnostic test for these…
Latest research from the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, recently published in the prestigious journal Cancer Discovery,…
Latest research at VHIO validates Myc inhibition as an effective therapeutic strategy against brain tumors The Myc protein also plays…
Aimed at exploring all aspects of the translational research continuum, from early detection through treatment to survivorship, this special 5-day…
